Abstract
BackgroundMultiple clinical trials have shown an overall improved response rate in hepatocellular carcinoma (HCC) by combining radiotherapy (RT) with immunotherapy (IO), however, treatment rates remain low and unpredictable.1 The suboptimal...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
